Cost of Zepbound: What You'll Actually Pay in 2025

Zepbound List Price vs. What Most Patients Pay

Zepbound's published Wholesale Acquisition Cost is approximately $1,059 per month regardless of dose, because Eli Lilly uses a flat pricing model across the 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials. The number that matters more for most patients is the out-of-pocket figure after savings programs. Commercially insured patients who are not on Medicare or Medicaid can use the Zepbound savings card to pay as little as $25 per month, with a maximum benefit of approximately $573 per fill. That card is not available to federal program beneficiaries.

Without insurance and without a savings card, you pay close to list. Lilly also sells Zepbound in single-dose vials directly through LillyDirect at a self-pay price ranging from $399 for a 2.5 mg or 5 mg monthly supply to $549 for higher maintenance doses. That direct-to-patient channel launched in early 2024 and represents one of the few genuine list-price reductions a major brand has offered in this class.

The clinical case for the cost is supported by SURMOUNT-1 (N=2,539), where participants on tirzepatide 15 mg lost a mean 22.5% of body weight over 72 weeks compared with 2.4% on placebo (P<0.001) [1]. For a 250-pound patient, that translates to roughly 56 pounds of mean loss at the highest dose.

Wegovy Cost: List Price, Savings, and Insurance Reality

Wegovy (semaglutide 2.4 mg, Novo Nordisk) carries a list price near $1,349 per month for the maintenance dose, making it the most expensive branded GLP-1 in the weight-loss category as of mid-2025. Novo Nordisk's NovoCare savings program can reduce that to as low as $0 per month for qualifying commercially insured patients or $99 per month for uninsured patients in certain circumstances, though eligibility rules change periodically.

Insurance coverage for Wegovy is inconsistent. Most commercial plans that cover anti-obesity medications will authorize Wegovy for patients meeting the label criteria: BMI <30 kg/m2, or BMI <27 kg/m2 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [2]. The Wegovy FDA label specifies adjunctive use with "a reduced-calorie diet and increased physical activity" [2].

STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% on placebo [3]. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events on semaglutide 2.4 mg versus placebo in adults with overweight or obesity and established cardiovascular disease, which has strengthened payer willingness to cover the drug for high-risk patients [4].

Ozempic Cost: The Off-Label Weight Loss Scenario

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) lists at roughly $968 per month for the 2 mg pen. It is FDA-approved only for type 2 diabetes management, not for chronic weight management, yet it is frequently prescribed off-label for weight loss because some insurance plans cover it more readily for a diabetes diagnosis than Wegovy for obesity [5].

Patients with type 2 diabetes and commercial insurance typically pay $25 or less per month with the Ozempic savings card. Medicare Part D covers Ozempic for T2D but, by statute (Social Security Act Section 1860D-2(e)(1)), cannot cover any drug used "for weight loss" as a primary indication, meaning Wegovy remains excluded regardless of the plan's formulary.

STEP-2 (N=1,210) tested semaglutide 1 mg in adults with type 2 diabetes and found 9.6% mean weight loss at 68 weeks versus 3.4% on placebo [6]. The STEP-8 head-to-head trial (N=338) compared semaglutide 2.4 mg with liraglutide 3 mg and found 15.8% versus 6.4% mean weight loss at 68 weeks, confirming semaglutide's superiority in the GLP-1 class [7].

Mounjaro Cost and Its Relationship to Zepbound

Mounjaro (tirzepatide, Eli Lilly) is the same molecule as Zepbound but FDA-approved for type 2 diabetes rather than obesity. Its list price sits near $1,069 per month. The Mounjaro savings card allows eligible commercially insured patients to pay as little as $25 per month, essentially the same structure as Zepbound.

Clinicians sometimes prescribe Mounjaro off-label for weight loss in patients who have concurrent type 2 diabetes, where insurance coverage is more predictable. SURMOUNT-2 (N=938) enrolled adults with type 2 diabetes and found tirzepatide 15 mg produced 15.7% mean weight loss at 72 weeks versus 3.3% on placebo [8]. That is nearly double the weight loss seen with semaglutide 1 mg in a comparable diabetic population (STEP-2).

The practical question most patients face is whether Mounjaro or Zepbound is covered. Employer-sponsored commercial plans with anti-obesity coverage typically prefer Zepbound because it carries the obesity indication, while plans covering only metabolic drugs prefer Mounjaro for patients with a documented T2D diagnosis. Checking both formularies before the prescription is written can save hundreds of dollars per month.

Compounded GLP-1 Costs: Tirzepatide and Semaglutide

Compounded tirzepatide and semaglutide became widely available in 2023 and 2024 when the FDA placed both branded drugs on its drug shortage list. Licensed 503A and 503B compounding pharmacies could legally produce copies during that shortage period. The FDA removed semaglutide from the shortage list in March 2024 and finalized tirzepatide's removal in mid-2024, triggering enforcement actions that required most telehealth compounders to phase out identical compounded formulations.

As of 2025, compounded GLP-1 pricing through telehealth platforms ranges from approximately $199 to $399 per month for semaglutide preparations and $299 to $549 per month for tirzepatide preparations, depending on dose and the specific 503A pharmacy fulfilling the order. These prices are roughly 60 to 80 percent below brand list prices.

The FDA has issued guidance stating that compounded drugs are not FDA-approved and lack the same safety and efficacy review as branded products [9]. Patients considering compounded options should confirm the pharmacy holds a valid state license and, for 503B facilities, an FDA registration. The American Association of Clinical Endocrinology (AACE) clinical practice guidelines emphasize using evidence-based, approved pharmacotherapy as the first-line approach for patients with BMI <30 kg/m2 plus comorbidities [10].

STEP-5 followed semaglutide 2.4 mg participants for 104 weeks and found sustained 15.2% mean weight loss maintained through two full years [11], supporting the case that branded formulations with documented long-term data offer a verifiable clinical track record that compounded products cannot match by definition.

Insurance Coverage Rules That Drive Your Real Cost

Insurance decisions on GLP-1 drugs follow three broad channels: commercial plans, Medicare, and Medicaid.

Commercial plans vary enormously. A 2023 survey by the Kaiser Family Foundation found that fewer than half of large employers covered anti-obesity medications in 2022, though that figure is rising as SELECT cardiovascular data have reframed obesity as a cardiovascular risk factor rather than a lifestyle choice. Step therapy requirements often mandate a trial of an older agent such as phentermine/topiramate before authorizing Wegovy or Zepbound.

Medicare Part D cannot cover weight-loss drugs by federal statute. Ozempic and Mounjaro are covered only when a type 2 diabetes diagnosis is on file. The Inflation Reduction Act did not change this restriction. Advocacy groups are pressing Congress for a legislative fix through the Treat and Reduce Obesity Act, which had not passed as of the date of this article.

Medicaid varies by state. A handful of states, including California and Illinois, have added GLP-1 anti-obesity coverage for Medicaid enrollees, while most have not. Patients should contact their state Medicaid office directly for current formulary information.

STEP-3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy and found 16.0% mean weight loss at 68 weeks [12], suggesting that pairing the medication with structured lifestyle support may improve outcomes enough to strengthen the insurance authorization case for patients whose initial requests are denied.

Savings Programs, Prior Authorization, and Appeals

Every major manufacturer offers a savings card or patient assistance program. The practical workflow for new patients is:

1. Confirm diagnosis codes. Obesity (ICD-10 E66.x) or type 2 diabetes (E11.x) must appear on the prior authorization form.
2. Submit the PA with BMI documentation. Most plans require BMI <30 or BMI <27 with a qualifying comorbidity.
3. Apply the manufacturer savings card at the pharmacy at the same time the PA is approved, not after. Savings cards cannot be combined with government insurance.
4. If the PA is denied, request a peer-to-peer review. A prescribing physician speaking directly with the insurance medical director overturns initial denials at rates between 30% and 50% in obesity medicine practice.
5. Escalate to a formal appeal using SELECT and SURMOUNT trial data if the peer-to-peer fails.

"Antiobesity medications should be considered for patients with obesity who have not achieved clinically meaningful weight loss through lifestyle intervention alone," according to published AACE/ACE obesity guidelines [10]. Citing guideline language explicitly in an appeal letter adds weight to the clinical justification.

SURMOUNT-3 (N=579) enrolled patients who had already achieved approximately 6.9% weight loss through a low-calorie diet and found tirzepatide produced an additional 18.4% weight loss over 36 weeks versus 2.5% on placebo [13], evidence that these drugs work even after initial lifestyle intervention, which can reinforce medical necessity arguments for insurers who claim diet and exercise should be tried first.

Long-Term Cost Considerations

A single monthly prescription is not the full cost picture. Dose escalation schedules for both semaglutide and tirzepatide require four to five months of lower-dose pens before reaching maintenance doses. During that period, the list-price cost is the same as the maintenance phase because Lilly and Novo use flat per-pen pricing.

Patients who stop the medication regain weight. SURMOUNT-4 (N=670) found that participants who discontinued tirzepatide after 36 weeks of treatment regained approximately two-thirds of their lost weight over the following 52 weeks versus continued loss of an additional 5.5% on the drug [14]. That finding has direct cost implications: this is effectively a chronic medication, and the annual spend at $1,059 per month list price runs to approximately $12,700 per year before any discounts.

For patients paying compounded prices in the $299 to $399 per month range, the annual figure drops to $3,600 to $4,800. The gap is real. Whether it translates to equivalent clinical outcomes depends on formulation quality, the dose accuracy of the compounded preparation, and the stability of the active peptide, none of which are independently verified by the FDA for compounded products.

Side-Effect-Related Costs

Nausea, vomiting, and diarrhea affect a meaningful share of patients during dose escalation and may require additional clinical visits or antiemetic prescriptions. In SURMOUNT-1, gastrointestinal adverse events led to discontinuation in 4.3% of tirzepatide-treated participants [1]. In STEP-1, the discontinuation rate for GI events was 4.5% on semaglutide 2.4 mg [3]. Budget for one or two extra telehealth visits during the first three months.

Gallbladder disease is another consideration. Rapid weight loss from any cause increases cholelithiasis risk. The Wegovy label notes cholelithiasis in 2.4% of semaglutide-treated patients versus 1.0% on placebo in pooled STEP trial data [2]. Cholecystectomy, if needed, adds several thousand dollars in out-of-pocket surgical cost even with insurance.

Comparing Total Annual Costs Across Options

| Drug | Annual List Price | With Savings Card | Compounded Alternative | |---|---|---|---| | Zepbound (tirzepatide) | ~$12,700 | ~$300/yr | $3,600-$6,600 | | Mounjaro (tirzepatide) | ~$12,800 | ~$300/yr | $3,600-$6,600 | | Wegovy (semaglutide 2.4 mg) | ~$16,200 | $0-$1,200/yr | $2,400-$4,800 | | Ozempic (semaglutide, T2D) | ~$11,600 | ~$300/yr | $2,400-$4,800 |

List prices based on 2025 Wholesale Acquisition Cost data. Savings card figures assume continuous commercial insurance eligibility. Compounded ranges reflect observed 503A telehealth pricing as of Q2 2025.

Zepbound's LillyDirect self-pay vials at $399 to $549 per month represent a third channel that sits between full list price and compounded pricing, with the assurance of an FDA-approved, commercially manufactured product. Patients without insurance who want a branded option should ask their prescriber about LillyDirect enrollment before defaulting to a compounding pharmacy.